As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Compass’ most advanced product candidate tovecimig is currently in a Phase 2/3 trial “COMPANION-002” in patients with advanced biliary tract cancer with top-line results guided for end-of-Q1, notes the analyst, who believes the risk/reward heading into top-line results is “positive” based on reported monotherapy and chemotherapy combination data showing encouraging clinical activity in solid tumors and potential differentiation from prior generations of similar drugs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with a Buy at Guggenheim
- Compass Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline
- Two new option listings on February 11th
- Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential